ICIs based on PD-1/PD-L1 blockade (such as pembrolizumab and camrelizumab) were approved in China in 2021 for the treatment of refractory, recurrent and/or metastatic NPC 39. This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.